Since
Sep 22, 2022

Please visit News and Press Releases at FSD Pharma, for items since Sep 22, 2021.

Sep 22, 2021 

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

​

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has retained the services of Hybrid Financial Ltd. (“Hybrid”), North Equities Corp. (the "North Equities"), Looking Glass Capital Consultants (“Looking Glass”), Worldwide Media Solutions, LLC (“BGTV Direct”), KCSA Strategic Communications ("KCSA"), and Digi Messaging & Advertising (“Digi”)...

Sep 21, 2021 

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

​

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (“Lucid”)...

Aug 25, 2021 

FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals

​

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions in legal psychedelics and medical cannabis, announces today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (“Lucid”)...

June 14, 2021 

Lucid Psycheceuticals Announces Exclusive License to Develop Cutting-Edge Neurodegenerative Disease Therapeutics

​

Lucid Psycheceuticals Inc. (Lucid), a psychedelics-inspired company focusing on total brain health, today announced that it has entered into a world-wide license agreement with University Health Network (UHN), Canada’s top research hospital, granting Lucid exclusive rights to novel compounds for therapeutic applications in neurodegenerative disorders.